Polymorphism of A118G in μ-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population.
Previous studies have indicated a direct effect of μ-opioid receptors on tumor progression or recurrence. An A118G polymorphism in the μ-opioid receptor gene was believed to play an important role in this carcinogenic process. The aim of the present study was to investigate the association between the A118G polymorphism and the risk of esophageal squamous cell carcinoma (ESCC) in a Chinese population. The case-control study included 260 cancer patients and 291 controls from a Chinese Han and Chinese TuJia population in Enshi region, China. Genotypes were determined by TaqMan platform. Odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated using multivariate unconditional logistic regression. Compared with the G/G genotype, the A/A genotype exhibited a significantly elevated risk for ESCC (OR = 3.12, 95 % CI [1], 1.11-6.01). A significant interaction between the A118G polymorphism and age, smoking status, and family history of cancer was also found (OR = 2.25, 95 % CI 1.36-4.12; OR = 1.75, 95 % CI 1.23-2.32; OR = 3.14, 95 % CI 1.31-7.28, respectively). The A118G polymorphism in the μ-opioid receptor gene might be associated with the risk of ESCC in Chinese population.